Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after market close. The Zacks Consensus Estimate for sales and earnings is ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other best wide moat stocks to invest in. Russell Investments continues to monitor and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Rachel Wells is a Forbes contributor and freelance writer who covers remote and flexible working, freelancing, side hustles, skill development, and AI, for Gen Z and Millennials. She has been ...

Rachel Tashjian is the fashion critic for The Washington Post's Style section, covering fashion worn by the many and the few, including clothing seen on the runway, in politics, in entertainment ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

There are interview podcasts and then there's Wild Card. Rachel Martin rips up the typical interview script and invites guests to answer questions they've never been asked before about life's ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

The health sciences study all aspects of health, disease and healthcare. This field of study aims to develop knowledge, interventions and technology for use in healthcare to improve the treatment ...